Results 41 to 50 of about 896 (121)

Hormone Replacement Therapy for Menopausal Symptoms and the Risk of Cardiometabolic Disease: Current Evidence and Future Directions

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background The transition through menopause is accompanied by a series of adverse metabolic changes which are associated with an increased risk of cardiometabolic disease, a major cause of mortality in women after midlife. Whilst the indication for menopausal hormone replacement therapy (HRT) is the control of menopausal symptoms ...
Jiawen Dong, Sarah Hillman, Sharon Dixon, Anupa Shah, Radha Venkatakrishnan, Jeremy W. Tomlinson   +5 more
wiley   +1 more source

Cervical and vaginal microbiomes in early miscarriages and ongoing pregnancy with and without dydrogesterone usage [PDF]

, 2023
In this study, our objective was to analyze the cervical and vaginal microbiomes during early pregnancy among three groups: women with healthy ongoing pregnancies, women undergoing dydrogesterone treatment, and those who experienced miscarriages.
Smirnova, Yu., Burakova, I., Kozarenko, O., Lebedeva, O., Gryaznova, M.   +4 more
core  

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Differences Between Oral Tibolone and Estradiol Plus Dydrogesterone in Improving Bone Mineral Density in Peri- and Post-menopausal Women

Clinical and Experimental Obstetrics & Gynecology
Background: To retrospectively investigate the efficacy and influencing factors of tibolone and estradiol plus dydrogesterone in improving bone mineral density (BMD) in peri- and post-menopausal women, to provide a basis for clinical ...
Yan Zhou, Yang Zhou, Changbing Li, Huaping Li, Minfang Tao   +4 more
doaj   +1 more source

Additional dydrogesterone for the treatment of chronic endometritis treated with antibiotic in premenopausal women with endometrial polyps: a retrospective cohort study

BMC Women's Health, 2022
Background To assess the efficacy of dysdrogesterone in the treatment of chronic endometritis (CE) treated with antibiotic in premenopausal women with endometrial polyps (EPs).
Yue Liu, Xin Yu, Jing Huang, Chengchao Du, Honggui Zhou, Yamei Yang, Dacheng Qu   +6 more
doaj   +1 more source

Comparison of Dydrogesterone and GnRH-a Effects After Laparoscopic Surgery in Patients with Stage III and IV Endometriosis

International Journal of General Medicine, 2023
Ting Deng, Yin Lin, Li Chen, Jun-Ying Jiang Department of Obstetrics and Gynecology, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, 350001, People’s ...
Deng T, Lin Y, Chen L, Jiang JY
doaj  

Hormonal replacement therapy in postmenopausal women ≥50 years is associated with the incidence of glaucoma: Evidence from 6576 females in Finland

Acta Ophthalmologica, Volume 104, Issue 7, Page 742-749, November 2026.
Abstract Purpose Hormonal replacement therapy (HRT) in postmenopausal women appears to affect glaucoma risk, but findings are inconsistent. We aimed to explore whether the use of postmenopausal HRT plays a role in glaucoma development in Finland. Methods The main outcome variable was glaucoma incidence measured by initiation of special reimbursement ...
Sirpa Loukovaara, Jari Haukka
wiley   +1 more source

Case‐malformed signal detection and prioritisation using EUROmediCAT data for pharmacovigilance in pregnancy

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3586-3597, October 2026.
Aim Many women take medications during pregnancy. However, the risk to the fetus from most medications is uncertain. Congenital anomalies are one of the leading causes of infant death and contribute to long‐term disability. Signal detection methods can be used to systematically identify possible medication–anomaly associations that require further ...
Hannah Johnson, Helen Dolk, Maria Loane, Christine Damase‐Michel, Joanne Given, Hedvig Nordeng, Jorieke E. H. Bergman, Iain Carey, Elly Den Hond, Ester Garne, Florence Rouget, Lea Bruneau, Isabelle Monier, Anke Rissmann, Mary O'Mahony, Miriam Gatt, Renée Lutke, Joanna Sichitiu, Elisa Ballardini, Alessio Coi, Clara Cavero Carbonell, David Tucker, Joan Morris   +22 more
wiley   +1 more source

Hormone therapy (HT) in women with premature ovarian insufficiency or early menopause: Time to think of a new paradigm for healthy aging. A joint FIGO and IMS position paper

International Journal of Gynecology &Obstetrics, Volume 175, Issue 1, Page 26-47, October 2026.
Abstract Premature ovarian insufficiency (POI) and early menopause (EM) affect millions of women worldwide. Compared with normal menopause, they confer a longer duration of estrogen deficiency and are associated not only with a shorter lifespan, but with a reduced healthspan, owing to an increased risk of cardiovascular, skeletal, cognitive and ...
Chiara Benedetto, Suvarna S. Khadilkar, Rossella E. Nappi, Andrea R. Genazzani, Federica Frezet, Laura Cucinella, Hema Divakar, Panagiotis Anagnostis, Nick Panay   +8 more
wiley   +1 more source

Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction

, 2019
The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards the most appropriate treatment option.
Macklon, Nick, Pexman-Fieth, Claire, Tournaye, Herman, Petraglia, Felice, Blockeel, Christophe, Griesinger, Georg, Arck, Petra, MS VPG/Gynaecologie, Georg Griesinger, van Amsterdam, Peter, Fauser, Bart CJM   +10 more
core   +1 more source